About this Journal Submit a Manuscript Table of Contents
International Journal of Proteomics
Volume 2011 (2011), Article ID 726869, 7 pages
Review Article

Lung Cancer Proteomics: Recent Advances in Biomarker Discovery

1Department of Human Pathology and Oncology, University of Siena, 53100 Siena, Italy
2Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
3Terni Human Health Bioscience Institute, Human Health Foundation, 05100 Terni, Italy
4Unit of Virology, “D. Cotugno” Hospital, 80123 Naples, Italy
5Committee on Biotechnologies and VirusSphere, World Academy of Biomedical Technologies, UNESCO, 75732 Paris, France

Received 14 March 2011; Accepted 16 July 2011

Academic Editor: Michael R. Emmert-Buck

Copyright © 2011 Paola Indovina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Lung cancer is the most common cause of cancer death in both men and women in Western countries, with a 5-year survival rate of 15%, which is among the lowest of all cancers. The high mortality from lung cancer is due not only to the late stage diagnosis but also to the lack of effective treatments even for patients diagnosed with stage I lung cancer. Therefore, there is an urgent need to identify new markers for early diagnosis and prognosis that could serve to open novel therapeutic avenues. Proteomics can represent an important tool for the identification of biomarkers and therapeutic targets for lung cancer since DNA-based biomarkers did not prove to have adequate sensitivity, specificity, and reproducibility. In this paper we will describe studies focused on the identification of new diagnostic, prognostic, and predictive markers for lung cancer, using proteomics technologies.